2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
Matt Krisiloff, chief executive officer of Conception Biosciences, has dozens of scientists working at a lab in Berkeley, Calif., trying to make eggs outside ovaries. Such a technique could allow women to have biological children later in life.